Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
20.11.2023 - Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, ... Seite 1
Dynamic International Prognostic Scoring System Spleen Volume Morphosys Chart Orphosys Kurs Morphosys Aktie
Source: wallstreet-online.de